Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial​

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial​

News published by Avalyn Pharma concerning AP01 (a formulation of pirfenidone optimized for delivery via inhalation), administered via an optimized eFlow® Technology nebulizer.
 

Read the press release